Silk Fibroin Industrialization Gains Momentum in GBA with GMP-grade Production

On September 5, 2026, the Greater Bay Area Silk Fibroin Industrialization Forum launched in Zhuhai. Hosted by Guangdong Maidi Biotech, a company founded just over a year ago, the event signaled the accelerating industrialization of silk fibroin in the GBA.

Pain Points and Technical Solutions

The industry faces four bottlenecks: sericin shielding and allergenicity; difficulty balancing purity and efficiency in traditional solubilization; lack of consistency in molecular weight customization; and production limited to lab-scale kilograms. Maidi introduced a "enzymatic hydrolysis-salting-out dual-process co-line technology." Its proprietary solubilization technique achieves rapid separation of enzymes and products, while chromatography reduces impurity risks. This platform allows precise customization from high-molecular-weight medical dressings to low-molecular-weight skincare ingredients, covering cosmetics, medical devices, and injectable-grade product lines.

Capacity Planning and Green Attributes

The company plans to build GMP-standard clean rooms with a designed annual capacity of 8 tons of silk fibroin. This scale addresses the stability and compliance pain points for downstream customers. Silk fibroin is a biodegradable material breaking down into amino acids and small peptides. The production process uses immobilized enzymes to reduce chemical solvent usage and optimizes salting-out to improve material utilization, aligning with green manufacturing trends.

Implications for B2B Purchasing and Brands

For procurement teams, the GMP-grade ton-level capacity resolves supply instability, allowing brands to shorten the cycle from raw material to finished goods. From a compliance perspective, silk fibroin, as a third-generation regenerative material, offers superior "active regeneration" mechanisms over traditional fillers, making it an ideal alternative to synthetic chemicals. Brands can leverage "one-stop" R&D and registration services to reduce multi-stage communication costs, capitalizing on regenerative medicine trends in medical aesthetics.